Last reviewed · How we verify
MMF, cyclosporine, steroids
This triple immunosuppressive regimen suppresses T-cell activation and proliferation through multiple pathways to prevent organ rejection.
This triple immunosuppressive regimen suppresses T-cell activation and proliferation through multiple pathways to prevent organ rejection. Used for Prevention of organ rejection in transplant recipients, Autoimmune and inflammatory conditions requiring immunosuppression.
At a glance
| Generic name | MMF, cyclosporine, steroids |
|---|---|
| Sponsor | Novartis |
| Drug class | Immunosuppressive combination therapy |
| Target | Multiple: IMPDH (MMF), calcineurin (cyclosporine), glucocorticoid receptor (steroids) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | Phase 3 |
Mechanism of action
MMF (mycophenolate mofetil) inhibits inosine monophosphate dehydrogenase to selectively suppress T and B cell proliferation. Cyclosporine blocks calcineurin signaling to prevent T-cell activation and cytokine production. Corticosteroids provide broad anti-inflammatory effects by suppressing multiple immune cell functions. Together, these agents provide complementary immunosuppression for transplant rejection prevention.
Approved indications
- Prevention of organ rejection in transplant recipients
- Autoimmune and inflammatory conditions requiring immunosuppression
Common side effects
- Infection (bacterial, viral, fungal)
- Nephrotoxicity
- Hypertension
- Hyperglycemia
- Gastrointestinal disturbances
- Tremor
- Gingival hyperplasia
Key clinical trials
- Tocilizumab in Cardiac Transplantation (PHASE2)
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy (PHASE3)
- Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation (PHASE4)
- Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft (PHASE4)
- Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR (PHASE2, PHASE3)
- Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease (PHASE1)
- Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |